CN1813741A - 含有氨氯地平和特拉唑嗪的药物组合物 - Google Patents
含有氨氯地平和特拉唑嗪的药物组合物 Download PDFInfo
- Publication number
- CN1813741A CN1813741A CN 200510004892 CN200510004892A CN1813741A CN 1813741 A CN1813741 A CN 1813741A CN 200510004892 CN200510004892 CN 200510004892 CN 200510004892 A CN200510004892 A CN 200510004892A CN 1813741 A CN1813741 A CN 1813741A
- Authority
- CN
- China
- Prior art keywords
- amlodipine
- terazosin
- active metabolite
- medicinal precursor
- medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 title claims abstract description 240
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims abstract description 229
- 229960000528 amlodipine Drugs 0.000 title claims abstract description 229
- 229960001693 terazosin Drugs 0.000 title claims abstract description 229
- 239000000203 mixture Substances 0.000 title abstract description 39
- 206010020772 Hypertension Diseases 0.000 claims abstract description 76
- 239000003814 drug Substances 0.000 claims abstract description 70
- 239000002243 precursor Substances 0.000 claims abstract description 64
- 150000003839 salts Chemical class 0.000 claims abstract description 53
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 64
- 239000002207 metabolite Substances 0.000 claims description 61
- 239000003826 tablet Substances 0.000 claims description 45
- 238000002360 preparation method Methods 0.000 claims description 33
- 230000001631 hypertensive effect Effects 0.000 claims description 26
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 24
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 21
- 239000002775 capsule Substances 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 16
- 238000013270 controlled release Methods 0.000 claims description 12
- 201000002327 urinary tract obstruction Diseases 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 3
- 229940077388 benzenesulfonate Drugs 0.000 claims description 3
- 239000007950 delayed release tablet Substances 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 abstract 4
- 238000011282 treatment Methods 0.000 description 43
- 230000036772 blood pressure Effects 0.000 description 33
- 230000003203 everyday effect Effects 0.000 description 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
- 241000700159 Rattus Species 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 25
- 229940079593 drug Drugs 0.000 description 22
- 229960001597 nifedipine Drugs 0.000 description 21
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 21
- 229940127291 Calcium channel antagonist Drugs 0.000 description 20
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 19
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 19
- 239000000480 calcium channel blocker Substances 0.000 description 19
- 229960001389 doxazosin Drugs 0.000 description 19
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 19
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 18
- 229920002472 Starch Chemical class 0.000 description 18
- 238000000576 coating method Methods 0.000 description 18
- 239000008107 starch Chemical class 0.000 description 18
- 235000019698 starch Nutrition 0.000 description 18
- 239000011248 coating agent Substances 0.000 description 17
- 210000002307 prostate Anatomy 0.000 description 17
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 15
- 229960004166 diltiazem Drugs 0.000 description 15
- 235000019359 magnesium stearate Nutrition 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 239000002220 antihypertensive agent Substances 0.000 description 11
- 229940127088 antihypertensive drug Drugs 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229960001289 prazosin Drugs 0.000 description 11
- 229960001909 terazosin hydrochloride Drugs 0.000 description 11
- 229960004005 amlodipine besylate Drugs 0.000 description 10
- 230000003276 anti-hypertensive effect Effects 0.000 description 10
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 10
- 230000001077 hypotensive effect Effects 0.000 description 9
- 230000002269 spontaneous effect Effects 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 150000003851 azoles Chemical class 0.000 description 8
- -1 dihydropyridine compound Chemical class 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 230000035488 systolic blood pressure Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010019280 Heart failures Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229940070764 terazosin 1 mg Drugs 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 208000007530 Essential hypertension Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 4
- 102000015009 alpha1-adrenergic receptor activity proteins Human genes 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000036724 intravesical pressure Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100024349 Alpha-1A adrenergic receptor Human genes 0.000 description 3
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 description 3
- 101000689685 Homo sapiens Alpha-1A adrenergic receptor Proteins 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 241000446313 Lamella Species 0.000 description 3
- 241001676635 Lepidorhombus whiffiagonis Species 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 3
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 3
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000036471 bradycardia Effects 0.000 description 3
- 208000006218 bradycardia Diseases 0.000 description 3
- 229960002467 bunazosin Drugs 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 229960002056 indoramin Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 description 3
- 229960002906 trimazosin Drugs 0.000 description 3
- 229960001130 urapidil Drugs 0.000 description 3
- 229960001722 verapamil Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 2
- TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 description 2
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 2
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 2
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940066481 amlodipine 10 mg Drugs 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008061 calcium-channel-blocking effect Effects 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229950008554 levamlodipine Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229960005425 nitrendipine Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008700 sympathetic activation Effects 0.000 description 2
- 229940005181 terazosin 5 mg Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OWGHROPUZICLBA-DJZRFWRSSA-N (2s)-2-[2-[[4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin-2-yl]methoxy]ethylamino]butanedioic acid Chemical compound CCOC(=O)C1=C(COCCN[C@@H](CC(O)=O)C(O)=O)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl OWGHROPUZICLBA-DJZRFWRSSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- TZNOWAJJWCGILX-HNUXRKMMSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl (4s)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl TZNOWAJJWCGILX-HNUXRKMMSA-N 0.000 description 1
- 239000004925 Acrylic resin Chemical class 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical class CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 102000008089 Myosin-Light-Chain Kinase Human genes 0.000 description 1
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000005276 aerator Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940077927 altace Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000035879 hyperinsulinaemia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 208000015658 resistant hypertension Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 206010046459 urethral obstruction Diseases 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
Abstract
Description
组别 | 给药后血压(mmHg) | ||
2h | 4h | 24h | |
模型组 | 182.6±14.3 | 185.6±8.6 | 183.3±10.9 |
氨氯地平(0.3mg/kg)+特拉唑嗪(0.1mg/kg) | 145.3±5.6**ab | 120.6±14.3**ab | 130.0±6.8**ab |
氨氯地平(0.3mg/kg) | 170.5±8.8**ab | 155.9±12.8** | 145.0±12.3* |
特拉唑嗪(0.1mg/kg) | 156.4±6.6** | 164.2±8.7** | 170.8±10.7 |
组别 | 给药后血压(mmHg) | 停药后(mmHg) | |||
7d | 14d | 24h | 48h | 72h | |
模型组 | 181.2±8.0 | 189.6±10.4 | 185.6±18.6 | 183.3±10.8 | 184.3±15.9 |
氨氯地平(0.3mg/kg)+特拉唑嗪(0.1mg/kg)氨氯地平(0.3mg/kg)特拉唑嗪(0.1mg/kg) | 120.6±14.7**ab140.8±15.3**150.0±13.5** | 124.7±12.8**ab138.3±8.9**157.7±7.0** | 132.6±14.3**ab145.9±12.8**163.2±14.7** | 135.0±6.8**ab150.0±14.5**176.8±10.7 | 150.0±5.8**165.0±9.3185.0±13.1 |
组别 | 连续给药第14天 | 停药24小时 |
模型组 | 180.3±11.9 | 179±15.6 |
氨氯地平(0.3mg/kg)+特拉唑嗪(0.1mg/kg) | 113.2±10.7*▲ | 130.8±6.0*▲ |
氨氯地平(0.5mg/kg)+多沙唑嗪(0.2mg/kg) | 130.2±9.4* | 150.6±7.8* |
硝苯地平(1mg/kg)+哌唑嗪(0.1mg/kg) | 136.2±14.8* | 170.6±14.8 |
硝苯地平(1mg/kg)+多沙唑嗪(0.2mg/kg) | 142.0±14.3* | 169.8±10.9 |
硝苯地平(1mg/kg)+特拉唑嗪(0.2mg/kg) | 144.2±7.9* | 176.4±8.3 |
阿芙唑嗪(0.3mg/kg)+硝苯地平(1mg/kg) | 141.2±8.3* | 169.0±11.0 |
地尔硫卓(12.5mg/kg)+哌唑嗪(0.3mg/kg) | 138.2±9.4* | 182.0±12.0 |
地尔硫卓(0.3mg/kg)+特拉唑嗪(0.5mg/kg) | 143.8±14.8* | 174.4±6.7 |
地尔硫卓(12.5mg/kg)+阿芙唑嗪(1mg/kg) | 153.6±8.8* | 172±13.1 |
前列腺PI:前列腺湿重(mg)/体重(100g) | 膀胱内压力(KPa) | 膀胱容量(mL) | 大鼠血压(mmHg) | ||
7天 | 14天 | ||||
对照组 | 196±25 | 0.46±0.09 | 0.25±0.08 | 184.2±11.0 | 180.5±7.9 |
模型组 | 347±43 | 1.45±0.21 | 0.52±0.10 | 186.3±11.6 | 183.0±74 |
氨氯地平(0.2mg/kg)+特拉唑嗪(0.3mg/kg) | 318±52 | 0.58±0.11*ab | 027±0.05*ab | 136.0±14.2*ab | 128.0±12.9*ab |
氨氯地平(0.2mg/kg) | 346±34 | 1.46±0.17 | 0.51±0.07 | 153.7±9.8* | 149.2±16.5* |
特拉唑嗪(0.3mg/kg) | 323±47 | 0.76±0.19* | 0.35±0.04* | 158.4±8.7* | 154.0±16.5* |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100048923A CN100540003C (zh) | 2005-02-03 | 2005-02-03 | 含有氨氯地平和特拉唑嗪的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100048923A CN100540003C (zh) | 2005-02-03 | 2005-02-03 | 含有氨氯地平和特拉唑嗪的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1813741A true CN1813741A (zh) | 2006-08-09 |
CN100540003C CN100540003C (zh) | 2009-09-16 |
Family
ID=36906175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100048923A Expired - Fee Related CN100540003C (zh) | 2005-02-03 | 2005-02-03 | 含有氨氯地平和特拉唑嗪的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100540003C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008052431A1 (fr) * | 2006-10-25 | 2008-05-08 | Beijing Huaanfo Biomedical Research Centre. Inc | Utilisation d'une composition contenant de l'amlodipine dans la preparation de medicaments destines au traitement d'un trouble de la voie urinaire inferieure |
CN101040860B (zh) * | 2006-03-22 | 2010-05-26 | 北京华安佛医药研究中心有限公司 | 治疗下尿路疾病的药物组合物 |
CN101890011B (zh) * | 2009-05-22 | 2013-05-01 | 北京奥萨医药研究中心有限公司 | 含有氨氯地平和己烯雌酚的药物组合物 |
-
2005
- 2005-02-03 CN CNB2005100048923A patent/CN100540003C/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101040860B (zh) * | 2006-03-22 | 2010-05-26 | 北京华安佛医药研究中心有限公司 | 治疗下尿路疾病的药物组合物 |
WO2008052431A1 (fr) * | 2006-10-25 | 2008-05-08 | Beijing Huaanfo Biomedical Research Centre. Inc | Utilisation d'une composition contenant de l'amlodipine dans la preparation de medicaments destines au traitement d'un trouble de la voie urinaire inferieure |
CN101890011B (zh) * | 2009-05-22 | 2013-05-01 | 北京奥萨医药研究中心有限公司 | 含有氨氯地平和己烯雌酚的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN100540003C (zh) | 2009-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1289082C (zh) | 用于治疗糖尿病的药物组合物 | |
CN1651087A (zh) | 有机化合物的联合形式 | |
JP6337170B2 (ja) | ネコの全身性疾患の予防又は治療の為のアンジオテンシンii受容体アンタゴニスト | |
CN1450895A (zh) | 雌激素药物药用组合物 | |
JP5968927B2 (ja) | 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用 | |
Inada et al. | Pharmacologic properties of candesartan cilexetil—possible mechanisms of long-acting antihypertensive action | |
CN1931167A (zh) | 非洛地平双层渗透泵控释药物组合物 | |
CN1765362A (zh) | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 | |
CN1931143A (zh) | 口服控制释放的曲美他嗪药物组合物 | |
CN1813741A (zh) | 含有氨氯地平和特拉唑嗪的药物组合物 | |
CA2471566A1 (en) | Combination of mtp inhibitors or apob-secretion inhibitors with fibrates for use as pharmaceuticals | |
CN101653440B (zh) | 含有氨氯地平系列盐和普利类药物的治疗组合物 | |
KR101303841B1 (ko) | 고혈압 및 대사증후군 질환 치료용 약학적 조성물 및 이의 용도 | |
CN1146418C (zh) | 血管紧张肽转化酶抑制剂和钙通道拮抗剂的定量结合物及其制备方法和在心血管疾病的治疗中的用途 | |
CN1610548A (zh) | 依贝沙坦在制备用来预防或治疗肺动脉高压的药物中的应用 | |
CN1269529C (zh) | 含有血管紧张素转化酶抑制剂和b族维生素的药物组合物 | |
CN1215845C (zh) | 盐酸地尔硫卓延迟缓释型微丸剂及其制备方法 | |
CN1286844C (zh) | 含有血管紧张素ⅱ受体拮抗剂和b族维生素的药物组合物 | |
CN1903189A (zh) | 含有坦索罗辛和钙拮抗剂的药物组合物 | |
CN101028518A (zh) | 含有硝酸酯类药物和伊伐布雷定的药物组合物 | |
CN1878548A (zh) | AT1拮抗物、阿米洛利或triameterine与一种利尿剂的组合 | |
CN1206991C (zh) | 含有盐酸西替利嗪和盐酸伪麻黄碱的制剂及其制备方法 | |
CN103083367B (zh) | 一种氯沙坦银杏叶复方制剂及其制备方法 | |
CN1827170A (zh) | 含有二氢吡啶类钙拮抗剂和苯氧芳酸类药物的组合物 | |
CN101040860A (zh) | 治疗下尿路疾病的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ANHUI HUA'ANFO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HUA'ANFO MEDICINE RESEARCH CENTER CO., LTD., BEIJING Effective date: 20121210 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100022 CHAOYANG, BEIJING TO: 230032 HEFEI, ANHUI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121210 Address after: 153, box 81, Medical University Of Anhui, 230032 Mei Shan Road, Anhui, Hefei Patentee after: Huaan Anhui Buddha Pharmaceutical Co.,Ltd. Address before: 100022 Beijing City, Chaoyang District No. 39 East Third Ring Road, SOHO8-2801 Patentee before: Beijng HAFO Biomedical Research Center, Inc. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal composition containing amlodipine and terazosine Effective date of registration: 20130523 Granted publication date: 20090916 Pledgee: China Everbright Bank Shenzhen Bagualing branch Pledgor: Huaan Anhui Buddha Pharmaceutical Co.,Ltd. Registration number: 2013990000311 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160705 Granted publication date: 20090916 Pledgee: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgor: Huaan Anhui Buddha Pharmaceutical Co.,Ltd. Registration number: 2013990000311 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20160705 Registration number: 2013990000311 Pledgee after: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgee before: China Everbright Bank Shenzhen Bagualing branch |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160926 Address after: 518057 Guangdong, Nanshan District high tech Zone in the middle of a high-tech incubator building 1-301 Patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Address before: 153, box 81, Medical University Of Anhui, 230032 Mei Shan Road, Anhui, Hefei Patentee before: Huaan Anhui Buddha Pharmaceutical Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: Three, No. 16 biological incubator No. 518057, high tech Zone, central high tech Zone, Shenzhen, Guangdong, Nanshan District Patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Address before: 518057 Guangdong, Nanshan District high tech Zone in the middle of a high-tech incubator building 1-301 Patentee before: SHENZHEN AUSA PHARMED Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090916 Termination date: 20220203 |